Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference
Adverum Biotechnologies (Nasdaq: ADVM), a clinical-stage company focused on gene therapy for ocular diseases, has announced its participation in the 2025 RBC Capital Markets Ophthalmology Virtual Conference. The company will engage in a fireside chat scheduled for Thursday, April 3 at 10:45 a.m. ET.
Interested parties can access the webcast through the Events and Presentations section of Adverum's website in the Investors area. The recording will remain available for a minimum of 30 days after the event.
Adverum Biotechnologies (Nasdaq: ADVM), un'azienda in fase clinica focalizzata sulla terapia genica per le malattie oculari, ha annunciato la sua partecipazione alla Conferenza Virtuale di Oftalmologia RBC Capital Markets 2025. L'azienda parteciperà a una chiacchierata informale programmata per giovedì 3 aprile alle 10:45 ET.
Le parti interessate possono accedere al webcast tramite la sezione Eventi e Presentazioni del sito web di Adverum nell'area Investitori. La registrazione rimarrà disponibile per un minimo di 30 giorni dopo l'evento.
Adverum Biotechnologies (Nasdaq: ADVM), una empresa en etapa clínica centrada en la terapia génica para enfermedades oculares, ha anunciado su participación en la Conferencia Virtual de Oftalmología de RBC Capital Markets 2025. La empresa participará en una charla informal programada para jueves 3 de abril a las 10:45 a.m. ET.
Las partes interesadas pueden acceder a la transmisión a través de la sección de Eventos y Presentaciones del sitio web de Adverum en el área de Inversores. La grabación estará disponible por un mínimo de 30 días después del evento.
Adverum Biotechnologies (Nasdaq: ADVM), 안과 질환을 위한 유전자 치료에 중점을 둔 임상 단계 회사가 2025 RBC 캐피탈 마켓 안과학 가상 회의에 참여한다고 발표했습니다. 회사는 4월 3일 목요일 오전 10시 45분 ET에 예정된 대담에 참여할 것입니다.
관심 있는 분들은 Adverum 웹사이트의 투자자 영역에 있는 이벤트 및 발표 섹션을 통해 웹캐스트에 접속할 수 있습니다. 녹화는 이벤트 후 최소 30일 동안 제공됩니다.
Adverum Biotechnologies (Nasdaq: ADVM), une entreprise en phase clinique axée sur la thérapie génique pour les maladies oculaires, a annoncé sa participation à la Conférence Virtuelle d'Ophthalmologie RBC Capital Markets 2025. L'entreprise participera à une discussion informelle prévue pour jeudi 3 avril à 10h45 ET.
Les parties intéressées peuvent accéder au webinaire via la section Événements et Présentations du site Web d'Adverum dans la zone Investisseurs. L'enregistrement restera disponible pendant un minimum de 30 jours après l'événement.
Adverum Biotechnologies (Nasdaq: ADVM), ein Unternehmen in der klinischen Phase, das sich auf Gentherapie für Augenerkrankungen konzentriert, hat seine Teilnahme an der 2025 RBC Capital Markets Ophthalmology Virtual Conference angekündigt. Das Unternehmen wird an einem informellen Gespräch teilnehmen, das für Donnerstag, den 3. April um 10:45 Uhr ET geplant ist.
Interessierte Parteien können über den Bereich Veranstaltungen und Präsentationen auf der Website von Adverum im Investorenbereich auf das Webcast zugreifen. Die Aufzeichnung bleibt mindestens 30 Tage nach der Veranstaltung verfügbar.
- None.
- None.
REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will participate in a fireside chat at the 2025 RBC Capital Markets Ophthalmology Virtual Conference on Thursday, April 3 at 10:45 a.m. ET.
The webcast of the fireside chat may be accessed under Events and Presentations in the Investors section of Adverum’s website. A replay of the webcast will be available on the website for at least 30 days following the event.
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.
Inquiries:
Adverum Investor Relations
Email: ir@adverum.com
FAQ
When is Adverum Biotechnologies (ADVM) presenting at the RBC Capital Markets Conference 2025?
How can investors access ADVM's presentation at the RBC Ophthalmology Conference?
How long will ADVM's RBC Conference presentation replay be available?
What is the focus of Adverum Biotechnologies' (ADVM) research and development?
